National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Klippel-Trénaunay Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Related Disorders List
Information on the following diseases can be found in the Related Disorders section of this report:
Klippel-Trénaunay syndrome (KTS) is a rare disorder that is present at birth (congenital) and is characterized by a triad of cutaneous capillary malformation ("port-wine stain"), lymphatic anomalies, and abnormal veins in association with variable overgrowth of soft tissue and bone. KTS occurs most frequently in the lower limb and less commonly in the upper extremity and trunk. KTS equally affects males and females.
The eponym KTS has generated controversy in the medical literature since the first report of the condition in the early 20th century. The French physicians, Klippel and Trénaunay, described patients with capillary stains (improperly called "hemangiomas" at that time), venous varicosities, and overgrowth. At about the same time, the English dermatologist Parkes Weber reported the combination of "hemangiomas" and overgrowth of a limb. For many years, the names of all three physicians were linked as a confusing (and incorrect) term "Klippel-Weber-Trénaunay syndrome," which still is (unfortunately) used to this day.
Since the latter 20th century, it is well-recognized that Parkes Weber and Klippel-Trénaunay syndromes are entirely different. Parkes Weber syndrome consists of fast-flow, multiple microscopic arteriovenous connections with variable capillary staining of an enlarged limb (usually the lower extremity). By genetic testing, many of these patients have a dominant, germline mutation in the gene RASA1.
In contrast, KTS is a slow-flow combined vascular disorder involving abnormal capillaries (C), lymphatics (L) and veins (V). Therefore, many investigators use the abbreviation CLVM, rather than KTS, and restrict the designation for patients who have all three vascular anomalies. Other authors apply the KTS term more broadly and include patients with only capillary stain (CM) or only capillary and venous anomalies (CVM) in the limb in the absence of lymphatic abnormalities.
Once the genetic cause for KTS is discovered, it will be possible to more precisely designate patients with these various combinations of vascular anomalies.
Capillary Malformation (CM)
At birth, KTS presents with scattered, geographic capillary stains. With age, the surface of the CM becomes studded with tiny lymphatic vesicles that often turn black due to intralesional bleeding.
Lymphatic Malformation (LM)
LM presents as localized or generalized overgrowth caused by micro- and macrocystic anomalies, sometimes in association with lymphedema. Often there is lymphatic swelling and fatty deposition on the contralateral foot. The lymphatic anomalies can also occur in the pelvis, bladder and lower gastrointestinal tract. Lymphatic cysts in the spleen are also common. LM is documented by ultrasonography and/or MRI. Lymphography shows that lymphedema is the result of diminished number or absence of lymphatic channels.
Episodic infections (cellulitis) are common and probably related to poor lymphatic drainage in the limb.
Venous Malformation (VM)
Venous abnormalities are always present but variable and involve the entire affected extremity. Typically there are anomalous embryonic veins called the "marginal system." Dilatation of superficial veins may not be apparent in infancy, but becomes more prominent with age. LM and VM can also involve the pelvic or abdominal organs resulting in bleeding from the rectum, vagina or urinary bladder. Abnormal fatty deposits accompany the venous and lymphatic anomalies.
Stagnant blood in the abnormal veins may clot and trigger a bleeding disorder called "disseminated intravascular coagulopathy."
Enlargement of the limb can be minimal to grotesque. Overgrowth in length is typical; however, in some patients the affected limb is shorter than normal. Frequently there is enlargement of the opposite foot.
The cause of KTS is unknown. The presumption is that it begins as a new gene mutation in primitive cells that form a limb that were destined to form blood and lymphatic vessels, fat, and bones. Researchers are actively trying to discover this mutation.
Klippel-Trénaunay Syndrome is a rare disorder affecting males and females in equal numbers. The disorder occurs worldwide.
KTS can be confused with other combined vascular disorders.
Parkes Weber syndrome
Tiny arteriovenous shunts in the thigh region have been found in KTS; however these are not clinically important. In contrast, multiple arteriovenous shunts and increased blood flow are the hallmarks of Parkes Weber syndrome.
In the past, patients with CLVM of the trunk were usually diagnosed as having KTS. Recently, it has been recognized that many of these patients have another, specific disorder of combined vascular anomalies and enlarged tissues designated by the acronym CLOVES = congenital lipomatous overgrowth with vascular anomalies, epidermal nevus and skeletal anomalies. CLOVES is caused by a somatic mutation in the gene PIK3CA.
KTS is diagnosed based on physical signs and symptoms. Computed axial tomography (CAT) and magnetic resonance imaging (MRI) scans, and color doppler studies may be useful in determining the scope of the syndrome and how best to manage it.
Recommended management for the following malformations associated with KTS is as follows:
The vesicles in the CM can be improved by laser therapy, sclerotherapy or sometimes
resection and closure or replacement with a split-thickness skin graft.
Macrocystic LM can be deflated by sclerotherapy (injection of irritating solutions), whereas, microcystic LM requires resection.
Blood stagnates in large dilated veins, and thus there is a risk for initiating a clotting disorder or thrombosis and pulmonary embolism. Anticoagulation with heparin is often necessary prior to radiologic or surgical intervention. Large venous channels can be obliterated by sclerotherapy or endovascular laser. Chronic bleeding from the colon may require surgical resection. Bleeding lesions in the bladder can be controlled by laser done through a cystoscope. An elastic compressive stocking is often useful to minimize discomfort and swelling due to venous distension.
Enlarged toes may require amputation to narrow the foot and permit footwear. Discrepancy in leg length can be corrected by inserting a lift in the shoe on the normal foot to prevent compensatory curvature of the spine (scoliosis). Surgical closure of the growth plate at the knee (epiphysiodesis) is often needed to equalize leg length.
Staged contour resection is possible to diminish girth of the limb. These procedures are less effective if the abnormal fat and vasculature extends beneath the deep fascia of the leg into the muscle layer.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Contact for additional information about Klippel-Trénaunay syndrome:
John B. Mulliken, MD,
Co-Director, Vascular Anomalies Center
Director, Craniofacial Centre
Boston Children's Hospital
300 Longwood Avenue
Boston, MA 02115
Oduber CEU, van der Horst CMAM, Hennekam RCM. Klippel-Trénaunay syndrome: diagnostic criteria and hypothesis on etiology. Ann Plast Surg. 2008;60(2):217-23.
Delis KT, Gloviczki P, Wennberg T, et al. Hemodynamic impairment, venous segmental disease (VSDS) and clinical severity (VCSS) scoring in limbs with Klippel-Trénaunay syndrome. J. Vasc.Surg. 2007;45:56-567.
Husmann DA, Rathburn SR, Driscoll DJ. Klippel-Trénaunay syndrome: incidence and treatment of genitourinary sequelae. J Urol. 2007;177(4):1244-9.
Cohen MM Jr. Klippel-Trénaunay syndrome. Am J Med Genet. 2000 Jul;93(3):171-5.
Jacob A, Driscoll D, Shaugnessy W, et al. Klippel-Trénaunay syndrome: Its spectrum and management . Mayo Clinic Proc. 1998;73:28-36
Happle R. Klipple-Trénaunay syndrome: Is it a paradominant trait? Br J. Dermatol. 1993;128:465-66.
Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Klippel-Trénaunay-Weber syndrome. Entry No: 149000. Last Edited July 3, 2012. Available at: http://www.ncbi.nlm.nih.gov/omim/. Accessed July 12, 2012.
March of Dimes Birth Defects Foundation
1275 Mamaroneck Avenue
White Plains, NY 10605
Klippel-Trenaunay Support Group
1471 Greystone Lane
Milford, OH 45150
8 Silver Ave
Ontario, M6R 1X8
PO Box 241956
Los Angeles, CA 90024
National Organization of Vascular Anomalies
PO Box 38216
Greensboro, NC 27438-8216
4581 Magnolia Dr.
Suffolk, VA 23435
Venous Disease Coalition
1075 S. Yukon Street, Suite 320
Lakewood, CO 80226
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email email@example.com
Last Updated: 7/12/2012
Copyright 1987, 1990, 1998, 2000, 2002, 2008, 2012 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.